Antimicrobial susceptibility testing for Helicobacter pylori in times of increasing antibiotic resistance

World Journal of Gastroenterology

Volumn , Issue 29, 2014, Pages 9912-9921

  Smith, Sinéad M ^a,b   O'Morain, Colm ^a   McNamara, Deirdre ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antibiotic resistance; Antimicrobial susceptibility testing; Helicobacter pylori; Molecular test; Polymerase chain reaction

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; DNA TOPOISOMERASE (ATP HYDROLYSING); LEVOFLOXACIN; METRONIDAZOLE; PROTON PUMP INHIBITOR; RIFAMPICIN; TETRACYCLINE; BISMUTH SALT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; CHRONIC GASTRITIS; COST EFFECTIVENESS ANALYSIS; DISK DIFFUSION; DNA REPLICATION; DUODENUM ULCER; GENE MUTATION; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MARGINAL ZONE LYMPHOMA; MINIMUM INHIBITORY CONCENTRATION; MOLECULAR GENETICS; NONHUMAN; NUCLEOTIDE SEQUENCE; PENICILLIN ALLERGY; POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; STOMACH CANCER; ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; BACTERIAL LOAD; BACTERIAL STRAIN; CANCER GROWTH; DIAGNOSTIC ACCURACY; DISEASE ERADICATION; DNA SEQUENCE; DRUG USE; FALSE NEGATIVE RESULT; GENETIC IDENTIFICATION; POINT MUTATION; PREVALENCE; REAL TIME POLYMERASE CHAIN REACTION; SEROLOGY; STOMACH BIOPSY; STOMACH ULCER; TREATMENT FAILURE; DRUG EFFECTS; GENETICS; GENOTYPE; HELICOBACTER INFECTIONS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MOLECULAR DIAGNOSIS; MUTATION; PATHOGENICITY; PATIENT SELECTION; PREDICTIVE VALUE; TREATMENT OUTCOME;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MICROBIAL SENSITIVITY TESTS; MOLECULAR DIAGNOSTIC TECHNIQUES; MUTATION; PATIENT SELECTION; PREDICTIVE VALUE OF TESTS; TREATMENT OUTCOME;

EID: 84905841921     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i29.9912     Document Type: Review

References (96)

1. Polk DB, Peek RM. Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010; 10: 403-414 [PMID: 20495574 DOI: 10.1038/nrc2857]
2. McColl KE. Clinical practice. Helicobacter pylori infection. N Engl J Med 2010; 362: 1597-1604 [PMID: 20427808 DOI: 10.1056/NEJMcp1001110]
3. Malfertheiner P, Megraud F, O'Morain CA, Atherton J, Axon AT, Bazzoli F, Gensini GF, Gisbert JP, Graham DY, Rokkas T, El-Omar EM, Kuipers EJ. Management of Helicobacter pylori infection - the Maastricht IV/Florence Consensus Report. Gut 2012; 61: 646-664 [PMID: 22491499 DOI: 10.1136/gutjnl-2012-302084]
4. Ierardi E, Giorgio F, Losurdo G, Di Leo A, Principi M. How antibiotic resistances could change Helicobacter pylori treatment: A matter of geography? World J Gastroenterol 2013; 19: 8168-8180 [PMID: 24363506 DOI: 10.3748/wjg.v19.i45.8168]
5. Iwańczak F, Iwańczak B. Treatment of Helicobacter pylori infection in the aspect of increasing antibiotic resistance. Adv Clin Exp Med 2012; 21: 671-680 [PMID: 23356205]
6. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 1994; 61: 177-240
7. Vaira D, Vakil N. Blood, urine, stool, breath, money, and Helicobacter pylori. Gut 2001; 48: 287-289 [PMID: 11171812]
8. Gisbert JP, Pajares JM. Review article: 13C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 2004; 20: 1001-1017 [PMID: 15569102 DOI: 10.1111/j.1365-2036.2004.02203.x]
9. Gisbert JP, Pajares JM. Stool antigen test for the diagnosis of Helicobacter pylori infection: a systematic review. Helicobacter 2004; 9: 347-368 [PMID: 15270750 DOI: 10.1111/j.1083-4389.2004.00235.x]
10. Gisbert JP, de la Morena F, Abraira V. Accuracy of monoclonal stool antigen test for the diagnosis of H. pylori infection: a systematic review and meta-analysis. Am J Gastroenterol 2006; 101: 1921-1930 [PMID: 16780557 DOI: 10.1111/j.1572-0241.2006.00668.x]
11. Deguchi R, Matsushima M, Suzuki T, Mine T, Fukuda R, Nishina M, Ozawa H, Takagi A. Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy. J Gastroenterol 2009; 44: 713-716 [PMID: 19458898 DOI: 10.1007/s00535-009-0069-z]
12. Loy CT, Irwig LM, Katelaris PH, Talley NJ. Do commercial serological kits for Helicobacter pylori infection differ in accuracy? A meta-analysis. Am J Gastroenterol 1996; 91: 1138-1144 [PMID: 8651160]
13. Feldman RA, Deeks JJ, Evans SJ. Multi-laboratory comparison of eight commercially available Helicobacter pylori serology kits. Helicobacter pylori Serology Study Group. Eur J Clin Microbiol Infect Dis 1995; 14: 428-433 [PMID: 7556232]
14. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007; 56: 772-781 [PMID: 17170018 DOI: 10.1136/gut.2006.101634]
15. Chey WD, Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007; 102: 1808-1825 [PMID: 17608775 DOI: 10.1111/j.1572-0241.2007.01393.x]
16. Jonkers D, Stobberingh E, de Bruine A, Arends JW, Stockbrügger R. Evaluation of immunohistochemistry for the detection of Helicobacter pylori in gastric mucosal biopsies. J Infect 1997; 35: 149-154 [PMID: 9354349]
17. Marzio L, Angelucci D, Grossi L, Diodoro MG, Di Campli E, Cellini L. Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy. Am J Gastroenterol 1998; 93: 223-226 [PMID: 9468247 DOI: 10.1111/j.1572-0241.1998.00223.x]
18. Sepulveda AR, Patil M. Practical approach to the pathologic diagnosis of gastritis. Arch Pathol Lab Med 2008; 132: 1586-1593 [PMID: 18834216]
19. McNulty CA, Lasseter G, Shaw I, Nichols T, D'Arcy S, Lawson AJ, Glocker E. Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered? Aliment Pharmacol Ther 2012; 35: 1221-1230 [PMID: 22469191 DOI: 10.1111/j.1365-2036.2012.05083.x]
20. Hentschel E, Brandstätter G, Dragosics B, Hirschl AM, Nemec H, Schütze K, Taufer M, Wurzer H. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-312 [PMID: 8419816 DOI: 10.1056/NEJM199302043280503]
21. Axon AT, O'Moráin CA, Bardhan KD, Crowe JP, Beattie AD, Thompson RP, Smith PM, Hollanders FD, Baron JH, Lynch DA, Dixon MF, Tompkins DS, Birrell H, Gillon KR. Randomised double blind controlled study of recurrence of gastric ulcer after treatment for eradication of Helicobacter pylori infection. BMJ 1997; 314: 565-568 [PMID: 9055715]
22. Leung WK, Lin SR, Ching JY, To KF, Ng EK, Chan FK, Lau JY, Sung JJ. Factors predicting progression of gastric intestinal metaplasia: results of a randomised trial on Helicobacter pylori eradication. Gut 2004; 53: 1244-1249 [PMID: 15306578 DOI: 10.1136/gut.2003.034629]
23. Wong BC, Lam SK, Wong WM, Chen JS, Zheng TT, Feng RE, Lai KC, Hu WH, Yuen ST, Leung SY, Fong DY, Ho J, Ching CK, Chen JS. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 2004; 291: 187-194 [PMID: 14722144 DOI: 10.1001/jama.291.2.187]
24. Malfertheiner P, Sipponen P, Naumann M, Moayyedi P, Mégraud F, Xiao SD, Sugano K, Nyrén O. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 2005; 100: 2100-2115 [PMID: 16128957 DOI: 10.1111/j.1572-0241.2005.41688.x]
25. Correa P, Fontham ET, Bravo JC, Bravo LE, Ruiz B, Zarama G, Realpe JL, Malcom GT, Li D, Johnson WD, Mera R. Chemoprevention of gastric dysplasia: randomized trial of antioxidant supplements and anti-helicobacter pylori therapy. J Natl Cancer Inst 2000; 92: 1881-1888 [PMID: 11106679]
26. Mera R, Fontham ET, Bravo LE, Bravo JC, Piazuelo MB, Camargo MC, Correa P. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54: 1536-1540 [PMID: 15985559 DOI: 10.1136/gut.2005.072009]
27. You WC, Brown LM, Zhang L, Li JY, Jin ML, Chang YS, Ma JL, Pan KF, Liu WD, Hu Y, Crystal-Mansour S, Pee D, Blot WJ, Fraumeni JF, Xu GW, Gail MH. Randomized doubleblind factorial trial of three treatments to reduce the prevalence of precancerous gastric lesions. J Natl Cancer Inst 2006; 98: 974-983 [PMID: 16849680 DOI: 10.1093/jnci/djj264]
28. Take S, Mizuno M, Ishiki K, Nagahara Y, Yoshida T, Yokota K, Oguma K, Okada H, Shiratori Y. The effect of eradicating helicobacter pylori on the development of gastric cancer in patients with peptic ulcer disease. Am J Gastroenterol 2005; 100: 1037-1042 [PMID: 15842576 DOI: 10.1111/j.1572-0241.2005.41384.x]
29. Fuccio L, Zagari RM, Eusebi LH, Laterza L, Cennamo V, Ceroni L, Grilli D, Bazzoli F. Meta-analysis: can Helicobacter pylori eradication treatment reduce the risk for gastric cancer? Ann Intern Med 2009; 151: 121-128 [PMID: 19620164]
30. Fischbach W, Goebeler-Kolve ME, Dragosics B, Greiner A, Stolte M. Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series. Gut 2004; 53: 34-37 [PMID: 14684573]
31. Wotherspoon AC, Doglioni C, Diss TC, Pan L, Moschini A, de Boni M, Isaacson PG. Regression of primary low-grade B-cell gastric lymphoma of mucosa-associated lymphoid tissue type after eradication of Helicobacter pylori. Lancet 1993; 342: 575-577 [PMID: 8102719]
32. Chen LT, Lin JT, Tai JJ, Chen GH, Yeh HZ, Yang SS, Wang HP, Kuo SH, Sheu BS, Jan CM, Wang WM, Wang TE, Wu CW, Chen CL, Su IJ, Whang-Peng J, Cheng AL. Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma. J Natl Cancer Inst 2005; 97: 1345-1353 [PMID: 16174856 DOI: 10.1093/jnci/dji277]
33. Wündisch T, Thiede C, Morgner A, Dempfle A, Günther A, Liu H, Ye H, Du MQ, Kim TD, Bayerdörffer E, Stolte M, Neubauer A. Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. J Clin Oncol 2005; 23: 8018-8024 [PMID: 16204012 DOI: 10.1200/JCO.2005.02.3903]
34. Malfertheiner P, Mégraud F, O'Morain C, Bell D, Bianchi Porro G, Deltenre M, Forman D, Gasbarrini G, Jaup B, Misiewicz JJ, Pajares J, Quina M, Rauws E. Current European concepts in the management of Helicobacter pylori infection - the Maastricht Consensus Report. The European Helicobacter Pylori Study Group (EHPSG). Eur J Gastroenterol Hepatol 1997; 9: 1-2 [PMID: 9031888]
35. Fock KM, Katelaris P, Sugano K, Ang TL, Hunt R, Talley NJ, Lam SK, Xiao SD, Tan HJ, Wu CY, Jung HC, Hoang BH, Kachintorn U, Goh KL, Chiba T, Rani AA. Second Asia-Pacific Consensus Guidelines for Helicobacter pylori infection. J Gastroenterol Hepatol 2009; 24: 1587-1600 [PMID: 19788600 DOI: 10.1111/j.1440-1746.2009.05982.x]
36. O'Connor A, Molina-Infante J, Gisbert JP, O'Morain C. Treatment of Helicobacter pylori infection 2013. Helicobacter 2013; 18 Suppl 1: 58-65 [PMID: 24011247 DOI: 10.1111/hel.12075]
37. O'Connor JP, Taneike I, O'Morain C. Improving compliance with helicobacter pylori eradication therapy: when and how? Therap Adv Gastroenterol 2009; 2: 273-279 [PMID: 21180555 DOI: 10.1177/1756283X09337342]
38. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010; 59: 1143-1153 [PMID: 20525969 DOI: 10.1136/gut.2009.192757]
39. Wueppenhorst N, Stueger HP, Kist M, Glocker E. Identification and molecular characterization of triple- and quadrupleresistant Helicobacter pylori clinical isolates in Germany. J Antimicrob Chemother 2009; 63: 648-653 [PMID: 19190100 DOI: 10.1093/jac/dkp003]
40. Wüppenhorst N, Lenze F, Ross M, Kist M. Isolation and eradication of a clinical isolate of Helicobacter pylori resistant to five antimicrobials in Germany. J Antimicrob Chemother 2011; 66: 222-223 [PMID: 21051371 DOI: 10.1093/jac/dkq405]
41. Buzás GM. First-line eradication of Helicobacter pylori: are the standard triple therapies obsolete? A different perspective. World J Gastroenterol 2010; 16: 3865-3870 [PMID: 20712046 DOI: 10.3748/wjg.v16.i31.3865]
42. Megraud F, Coenen S, Versporten A, Kist M, Lopez-Brea M, Hirschl AM, Andersen LP, Goossens H, Glupczynski Y. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013; 62: 34-42 [PMID: 22580412 DOI: 10.1136/gutjnl-2012-302254]
43. Toracchio S, Capodicasa S, Soraja DB, Cellini L, Marzio L. Rifabutin based triple therapy for eradication of H. pylori primary and secondary resistant to tinidazole and clarithromycin. Dig Liver Dis 2005; 37: 33-38 [PMID: 15702857 DOI: 10.1016/j.dld.2004.09.008]
44. Gisbert JP, Bermejo F, Castro-Fernández M, Pérez-Aisa A, Fernández-Bermejo M, Tomas A, Barrio J, Bory F, Almela P, Sánchez-Pobre P, Cosme A, Ortiz V, Niño P, Khorrami S, Benito LM, Carneros JA, Lamas E, Modolell I, Franco A, Ortuño J, Rodrigo L, García-Durán F, O'Callaghan E, Ponce J, Valer MP, Calvet X. Second-line rescue therapy with levofloxacin after H. pylori treatment failure: a Spanish multicenter study of 300 patients. Am J Gastroenterol 2008; 103: 71-76 [PMID: 17764498 DOI: 10.1111/j.1572-0241.2007.01500.x]
45. Health Protection Agency UK. Investigation of gastric biopsies for Helicobacter pylori. Health Protection Agency Standards Unit, Standards and Evaluation laboratory 2012. Available from: URL: http://www.hpa.org.uk/webc/hpawebfile/hpaweb-c/1317132860197
46. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007; 20: 280-322 [PMID: 17428887 DOI: 10.1128/CMR.00033-06]
47. Dent JC, McNulty CA. Evaluation of a new selective medium for Campylobacter pylori. Eur J Clin Microbiol Infect Dis 1988; 7: 555-558 [PMID: 3141172]
48. EUCAST. Breakpoint tables for interpretation of MICs and zone diameters. 2013; Version 3.1. Available from: URL: http://www.eucast.org/fileadmin/src/media/PDFs/EUCAST-files/Consultation/EUCAST-clinical-breakpoints-for-Helicobacter-pylori.pdf
49. Savarino V, Zentilin P, Pivari M, Bisso G, Raffaella Mele M, Bilardi C, Borro P, Dulbecco P, Tessieri L, Mansi C, Borgonovo G, De Salvo L, Vigneri S. The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori. Aliment Pharmacol Ther 2000; 14: 893-900 [PMID: 10886045]
50. Pilotto A, Rassu M, Leandro G, Franceschi M, Di Mario F. Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer. Dig Liver Dis 2000; 32: 763-768 [PMID: 11215555]
51. Schwartz H, Krause R, Sahba B, Haber M, Weissfeld A, Rose P, Siepman N, Freston J. Triple versus dual therapy for eradicating Helicobacter pylori and preventing ulcer recurrence: a randomized, double-blind, multicenter study of lansoprazole, clarithromycin, and/or amoxicillin in different dosing regimens. Am J Gastroenterol 1998; 93: 584-590 [PMID: 9576452 DOI: 10.1111/j.1572-0241.1998.169-b.x]
52. Chisholm SA, Owen RJ. Application of polymerase chain reaction-based assays for rapid identification and antibiotic resistance screening of Helicobacter pylori in gastric biopsies. Diagn Microbiol Infect Dis 2008; 61: 67-71 [PMID: 18248939 DOI: 10.1016/j.diagmicrobio.2007.12.005]
53. Lehours P, Mégraud F. Helicobacter pylori molecular diagnosis. Expert Rev Mol Diagn 2011; 11: 351-355 [PMID: 21545252 DOI: 10.1586/erm.11.17]
54. Elviss NC, Lawson AJ, Owen RJ. Application of 3′-mismatched reverse primer PCR compared with real-time PCR and PCR-RFLP for the rapid detection of 23S rDNA mutations associated with clarithromycin resistance in Helicobacter pylori. Int J Antimicrob Agents 2004; 23: 349-355 [PMID: 15081083 DOI: 10.1016/j.ijantimicag.2003.09.015]
55. De Francesco V, Zullo A, Ierardi E, Giorgio F, Perna F, Hassan C, Morini S, Panella C, Vaira D. Phenotypic and genotypic Helicobacter pylori clarithromycin resistance and therapeutic outcome: benefits and limits. J Antimicrob Chemother 2010; 65: 327-332 [PMID: 20008044 DOI: 10.1093/jac/dkp445]
56. Sakinc T, Baars B, Wüppenhorst N, Kist M, Huebner J, Opferkuch W. Influence of a 23S ribosomal RNA mutation in Helicobacter pylori strains on the in vitro synergistic effect of clarithromycin and amoxicillin. BMC Res Notes 2012; 5: 603 [PMID: 23110798 DOI: 10.1186/1756-0500-5-603]
57. Cambau E, Allerheiligen V, Coulon C, Corbel C, Lascols C, Deforges L, Soussy CJ, Delchier JC, Megraud F. Evaluation of a new test, genotype HelicoDR, for molecular detection of antibiotic resistance in Helicobacter pylori. J Clin Microbiol 2009; 47: 3600-3607 [PMID: 19759218 DOI: 10.1128/JCM.00744-09]
58. Gibson JR, Saunders NA, Burke B, Owen RJ. Novel method for rapid determination of clarithromycin sensitivity in Helicobacter pylori. J Clin Microbiol 1999; 37: 3746-3748 [PMID: 10523591]
59. Agudo S, Alarcón T, Urruzuno P, Martínez MJ, López-Brea M. Detection of Helicobacter pylori and clarithromycin resistance in gastric biopsies of pediatric patients by using a commercially available real-time polymerase chain reaction after NucliSens semiautomated DNA extraction. Diagn Microbiol Infect Dis 2010; 67: 213-219 [PMID: 20542201 DOI: 10.1016/j.diagmicrobio.2010.02.021]
60. Chisholm SA, Owen RJ, Teare EL, Saverymuttu S. PCR-based diagnosis of Helicobacter pylori infection and real-time determination of clarithromycin resistance directly from human gastric biopsy samples. J Clin Microbiol 2001; 39: 1217-1220 [PMID: 11283030 DOI: 10.1128/JCM.39.4.1217-1220.2001]
61. Lehours P, Siffré E, Mégraud F. DPO multiplex PCR as an alternative to culture and susceptibility testing to detect Helicobacter pylori and its resistance to clarithromycin. BMC Gastroenterol 2011; 11: 112 [PMID: 22004003 DOI: 10.1186/1471-230X-11-112]
62. Vécsei A, Innerhofer A, Binder C, Gizci H, Hammer K, Bruckdorfer A, Riedl S, Gadner H, Hirschl AM, Makristathis A. Stool polymerase chain reaction for Helicobacter pylori detection and clarithromycin susceptibility testing in children. Clin Gastroenterol Hepatol 2010; 8: 309-312 [PMID: 20005978 DOI: 10.1016/j.cgh.2009.12.002]
63. Lottspeich C, Schwarzer A, Panthel K, Koletzko S, Rüssmann H. Evaluation of the novel Helicobacter pylori Clari-Res real-time PCR assay for detection and clarithromycin susceptibility testing of H. pylori in stool specimens from symptomatic children. J Clin Microbiol 2007; 45: 1718-1722 [PMID: 17392440 DOI: 10.1128/JCM.00103-07]
64. Schabereiter-Gurtner C, Hirschl AM, Dragosics B, Hufnagl P, Puz S, Kovách Z, Rotter M, Makristathis A. Novel real-time PCR assay for detection of Helicobacter pylori infection and simultaneous clarithromycin susceptibility testing of stool and biopsy specimens. J Clin Microbiol 2004; 42: 4512-4518 [PMID: 15472302 DOI: 10.1128/JCM.42.10.4512-4518.2004]
65. Scaletsky IC, Aranda KR, Garcia GT, Gonc¸alves ME, Cardoso SR, Iriya K, Silva NP. Application of real-time PCR stool assay for Helicobacter pylori detection and clarithromycin susceptibility testing in Brazilian children. Helicobacter 2011; 16: 311-315 [PMID: 21762271 DOI: 10.1111/j.1523-5378.2011.00845.x]
66. Wang LH, Cheng H, Hu FL, Li J. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol 2010; 16: 2272-2277 [PMID: 20458765]
67. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007; 51: 346-349 [PMID: 17043117 DOI: 10.1128/AAC.00614-06]
68. Glocker E, Berning M, Gerrits MM, Kusters JG, Kist M. Real-time PCR screening for 16S rRNA mutations associated with resistance to tetracycline in Helicobacter pylori. Antimicrob Agents Chemother 2005; 49: 3166-3170 [PMID: 16048919 DOI: 10.1128/AAC.49.8.3166-3170.2005]
69. Lawson AJ, Elviss NC, Owen RJ. Real-time PCR detection and frequency of 16S rDNA mutations associated with resistance and reduced susceptibility to tetracycline in Helicobacter pylori from England and Wales. J Antimicrob Chemother 2005; 56: 282-286 [PMID: 15958499 DOI: 10.1093/jac/dki199]
70. Vilaichone RK, Gumnarai P, Ratanachu-Ek T, Mahachai V. Nationwide survey of Helicobacter pylori antibiotic resistance in Thailand. Diagn Microbiol Infect Dis 2013; 77: 346-349 [PMID: 24094837 DOI: 10.1016/j.diagmicrobio.2013.08.010]
71. Gao W, Cheng H, Hu F, Li J, Wang L, Yang G, Xu L, Zheng X. The evolution of Helicobacter pylori antibiotics resistance over 10 years in Beijing, China. Helicobacter 2010; 15: 460-466 [PMID: 21083752 DOI: 10.1111/j.1523-5378.2010.00788.x]
72. Miendje Deyi VY, Burette A, Bentatou Z, Maaroufi Y, Bontems P, Lepage P, Reynders M. Practical use of GenoType® HelicoDR, a molecular test for Helicobacter pylori detection and susceptibility testing. Diagn Microbiol Infect Dis 2011; 70: 557-560 [PMID: 21696906 DOI: 10.1016/j.diagmicrobio.2011.05.002]
73. Zullo A, Hassan C, Cristofari F, Andriani A, De Francesco V, Ierardi E, Tomao S, Stolte M, Morini S, Vaira D. Effects of Helicobacter pylori eradication on early stage gastric mucosa-associated lymphoid tissue lymphoma. Clin Gastroenterol Hepatol 2010; 8: 105-110 [PMID: 19631287 DOI: 10.1016/j.cgh.2009.07.017]
74. Glupczynski Y, Mégraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-823 [PMID: 11783701]
75. Fischbach LA, van Zanten S, Dickason J. Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. Aliment Pharmacol Ther 2004; 20: 1071-1082 [PMID: 15569109 DOI: 10.1111/j.1365-2036.2004.02248.x]
76. Fischbach L, Evans EL. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Aliment Pharmacol Ther 2007; 26: 343-357 [PMID: 17635369 DOI: 10.1111/j.1365-2036.2007.03386.x]
77. Dore MP, Leandro G, Realdi G, Sepulveda AR, Graham DY. Effect of pretreatment antibiotic resistance to metronidazole and clarithromycin on outcome of Helicobacter pylori therapy: a meta-analytical approach. Dig Dis Sci 2000; 45: 68-76 [PMID: 10695616]
78. Oleastro M, Cabral J, Ramalho PM, Lemos PS, Paixão E, Benoliel J, Santos A, Lopes AI. Primary antibiotic resistance of Helicobacter pylori strains isolated from Portuguese children: a prospective multicentre study over a 10 year period. J Antimicrob Chemother 2011; 66: 2308-2311 [PMID: 21764826 DOI: 10.1093/jac/dkr293]
79. Malfertheiner P, Bazzoli F, Delchier JC, Celiñski K, Giguère M, Rivière M, Mégraud F. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial. Lancet 2011; 377: 905-913 [PMID: 21345487 DOI: 10.1016/S0140-6736(11)60020-2]
80. Bardhan K, Bayerdörffer E, Veldhuyzen Van Zanten SJ, Lind T, Mégraud F, Delchier JC, Hellblom M, Stubberöd A, Burman CF, Gromark P, Zeijlon L. The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. Helicobacter 2000; 5: 196-201 [PMID: 11179983]
81. O'Connor A, Taneike I, Nami A, Fitzgerald N, Murphy P, Ryan B, O'connor H, Qasim A, Breslin N, O'moráin C. Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland. Eur J Gastroenterol Hepatol 2010; 22: 1123-1127 [PMID: 20354442 DOI: 10.1097/MEG.0b013e328338e43d]
82. O'Connor A, Taneike I, Nami A, Fitzgerald N, Ryan B, Breslin N, O'Connor H, McNamara D, Murphy P, O'Morain C. Helicobacter pylori resistance rates for levofloxacin, tetracycline and rifabutin among Irish isolates at a reference centre. Ir J Med Sci 2013; 182: 693-695 [PMID: 23625165 DOI: 10.1007/s11845-013-0957-3]
83. Su P, Li Y, Li H, Zhang J, Lin L, Wang Q, Guo F, Ji Z, Mao J, Tang W, Shi Z, Shao W, Mao J, Zhu X, Zhang X, Tong Y, Tu H, Jiang M, Wang Z, Jin F, Yang N, Zhang J. Antibiotic resistance of Helicobacter pylori isolated in the Southeast Coastal Region of China. Helicobacter 2013; 18: 274-279 [PMID: 23418857 DOI: 10.1111/hel.12046]
84. Yamade M, Sugimoto M, Uotani T, Nishino M, Kodaira C, Furuta T. Resistance of Helicobacter pylori to quinolones and clarithromycin assessed by genetic testing in Japan. J Gastroenterol Hepatol 2011; 26: 1457-1461 [PMID: 21679250 DOI: 10.1111/j.1440-1746.2011.06815.x]
85. Lee JW, Kim N, Kim JM, Nam RH, Chang H, Kim JY, Shin CM, Park YS, Lee DH, Jung HC. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013; 18: 206-214 [PMID: 23241101 DOI: 10.1111/hel.12031]
86. Wenzhen Y, Yumin L, Quanlin G, Kehu Y, Lei J, Donghai W, Lijuan Y. Is antimicrobial susceptibility testing necessary before first-line treatment for Helicobacter pylori infection? Meta-analysis of randomized controlled trials. Intern Med 2010; 49: 1103-1109 [PMID: 20558925]
87. Romano M, Marmo R, Cuomo A, De Simone T, Mucherino C, Iovene MR, Montella F, Tufano MA, Del Vecchio Blanco C, Nardone G. Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2003; 1: 273-278 [PMID: 15017668]
88. Qasim A, Sebastian S, Buckley M, O'Connor H, O'Morain C. Pretreatment antimicrobial susceptibility testing is not cost saving in the standard eradication of Helicobacter pylori. Clin Gastroenterol Hepatol 2004; 2: 85; discussion 85 [PMID: 15017637]
89. Faber J, Bar-Meir M, Rudensky B, Schlesinger Y, Rachman E, Benenson S, Sirota G, Stankiewic H, Halle D, Wilschanski M. Treatment regimens for Helicobacter pylori infection in children: is in vitro susceptibility testing helpful? J Pediatr Gastroenterol Nutr 2005; 40: 571-574 [PMID: 15861018]
90. Cosme A, Montes M, Martos M, Gil I, Mendarte U, Salicio Y, Piñeiro L, Recasens MT, Ibarra B, Sarasqueta C, Bujanda L. Usefulness of antimicrobial susceptibility in the eradication of Helicobacter pylori. Clin Microbiol Infect 2013; 19: 379-383 [PMID: 22512623 DOI: 10.1111/j.1469-0691.2012.03844.x]
91. Fiorini G, Vakil N, Zullo A, Saracino IM, Castelli V, Ricci C, Zaccaro C, Gatta L, Vaira D. Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection. Clin Gastroenterol Hepatol 2013; 11: 507-510 [PMID: 23267869 DOI: 10.1016/j.cgh.2012.12.007]
92. Liou JM, Chen CC, Chang CY, Chen MJ, Fang YJ, Lee JY, Chen CC, Hsu SJ, Hsu YC, Tseng CH, Tseng PH, Chang L, Chang WH, Wang HP, Shun CT, Wu JY, Lee YC, Lin JT, Wu MS. Efficacy of genotypic resistance-guided sequential therapy in the third-line treatment of refractory Helicobacter pylori infection: a multicentre clinical trial. J Antimicrob Chemother 2013; 68: 450-456 [PMID: 23099849 DOI: 10.1093/jac/dks407]
93. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori. European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1992; 11: 777-781 [PMID: 1468415]
94. Tveit AH, Bruce MG, Bruden DL, Morris J, Reasonover A, Hurlburt DA, Hennessy TW, McMahon B. Alaska sentinel surveillance study of Helicobacter pylori isolates from Alaska Native persons from 2000 to 2008. J Clin Microbiol 2011; 49: 3638-3643 [PMID: 21813726 DOI: 10.1128/JCM.01067-11]
95. Abadi AT, Taghvaei T, Mobarez AM, Carpenter BM, Merrell DS. Frequency of antibiotic resistance in Helicobacter pylori strains isolated from the northern population of Iran. J Microbiol 2011; 49: 987-993 [PMID: 22203563 DOI: 10.1007/s12275-011-1170-6]
96. Seck A, Burucoa C, Dia D, Mbengue M, Onambele M, Raymond J, Breurec S. Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients. Ann Clin Microbiol Antimicrob 2013; 12: 3 [PMID: 23298145 DOI: 10.1186/1476-0711-12-3]